Stroke patients have a new hope for arm rehabilitation thanks to a team from UH. Photo courtesy of UH

Almost 800,000 people in the United States suffer from a stroke annually — and the affliction affects each patient differently. One University of Houston researcher has created a device that greatly improves the lives of patients whose stroke affected motor skills.

UH engineering professor Jose Luis Contreras-Vidal developed a next-generation robotic arm that can be controlled by the user's brainwaves. The portable device uses a brain-computer interface (BCI) developed by Contreras-Vidal. Stroke patient Oswald Reedus, 66, is the first person to use a device of this kind.

Reedus lost the use of his left arm following a stroke that also caused aphasia, or difficulty speaking. While he's been able to recover his ability to speak clearly, the new exoskeleton will help rehabilitate his arm.

When strapped into the noninvasive device, the user's brain activity is translated into motor commands to power upper-limb robotics. As patients like Reedus use the device, more data is collected to improve the experience.

“If I can pass along anything to help a stroke person’s life, I will do it. For me it’s my purpose in life now,” says Reedus in a news release from UH. His mother and younger brother both died of strokes, and Reedus is set on helping the device that can help other stroke patients recover.

Contreras-Vidal, a Hugh Roy and Lillie Cranz Cullen distinguished professor, has led his device from ideation to in-home use, like with Reedus, as well as clinical trials at TIRR Memorial Hermann. The project is funded in part from an $813,999 grant from the National Science Foundation’s newly created Division of Translational Impacts.

"Our project addresses a pressing need for accessible, safe, and effective stroke rehabilitation devices for in-clinic and at-home use for sustainable long-term therapy, a global market size expected to currently be $31 billion," Contreras-Vidal says in the release. "Unfortunately, current devices fail to engage the patients, are hard to match to their needs and capabilities, are costly to use and maintain, or are limited to clinical settings."

Dr. Gerard E. Francisco, chief medical officer and director of the Neuro Recovery Research Center at TIRR Memorial Hermann, is leading the clinical trials for the device. He's also chair and professor in the Department of Physical Medicine and Rehabilitation at McGovern Medical School at UTHealth Houston. He explains that TIRR's partnership with engineering schools such as the Cullen College of Engineering at UH and others around the nation is strategic.

“This is truly exciting because what we know now is there are so many ways we can induce neuroplasticity or how we can boost recovery,” says Francisco in the release. “That collaboration is going to give birth to many of these groundbreaking technologies and innovations we can offer our patients.”

Both parts of the device — a part that attaches to the patient's head and a part affixed to their arm — are noninvasive. Photo courtesy of UH

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston femtech co. debuts new lactation and wellness pods

mom pod

Houston-based femtech company Work&, previously known as Work&Mother, has introduced new products in recent months aimed at supporting working mothers and the overall health of all employees.

The company's new Lactation Pod and Hybrid Pod serve as dual-use lactation and wellness spaces to meet employer demand, the company shared in a news release. The compact pods offer flexible design options that can serve permanent offices and nearly all commercial spaces.

They feature a fully compliant lactation station while also offering wellness functionalities that can support meditation, mental health, telehealth and prayer. In line with Work&'s other spaces, the pods utilize the Work& scheduling platform, which prioritizes lactation bookings to help employers comply with the PUMP Act.

“This isn’t about perks,” Jules Lairson, Work& co-founder and COO, said in the release. “It’s about meeting people where they are—with dignity and intentional design. That includes the mother returning to work, the employee managing anxiety, and everyone in between.”

According to the company, several Fortune 500 companies are already using the pods, and Work& has plans to grow the products' reach.

Earlier this year, Work& introduced its first employee wellness space at MetroNational’s Memorial City Plazas, representing Work&'s shift to offer an array of holistic health and wellness solutions for landlords and tenants.

The company, founded in 2017 by Lairson and CEO Abbey Donnell, was initially focused on outfitting commercial buildings with lactation accommodations for working parents. While Work& still offers these services through its Work&Mother branch, the addition of its Work&Wellbeing arm allowed the company to also address the broader wellness needs of all employees.

The company rebranded as Work& earlier this year.

Rice biotech studio secures investment from Modi Ventures, adds founder to board

fresh funding

RBL LLC, which supports commercialization for ventures formed at the Rice University Biotech Launch Pad, has secured an investment from Houston-based Modi Ventures.

Additionally, RBL announced that it has named Sahir Ali, founder and general partner of Modi Ventures, to its board of directors.

Modi Ventures invests in biotech companies that are working to advance diagnostics, engineered therapeutics and AI-driven drug discovery. The firm has $134 million under management after closing an oversubscribed round this summer.

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. William McKeon, president and CEO of the TMC, previously called the launch of RBL a “critical step forward” for Houston’s life sciences ecosystem.

“RBL is dedicated to building companies focused on pioneering and intelligent bioelectronic therapeutics,” Ali said in a LinkedIn post. “This partnership strengthens the Houston biotech ecosystem and accelerates the transition of groundbreaking lab discoveries into impactful therapies.”

Ali will join board members like managing partner Paul Wotton, Rice bioengineering professor Omid Veiseh, scientist and partner at KdT Ventures Rima Chakrabarti, Rice alum John Jaggers, CEO of Arbor Biotechnologies Devyn Smith, and veteran executive in the life sciences sector James Watson.

Ali has led transformative work and built companies across AI, cloud computing and precision medicine. Ali also serves on the board of directors of the Drug Information Association, which helps to collaborate in drug, device and diagnostics developments.

“This investment by Modi Ventures will be instrumental to RBL’s growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups,” Wotton said in the announcement. "Sahir’s addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission.”